These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 10956209)

  • 1. CoMFA-based prediction of agonist affinities at recombinant wild type versus serine to alanine point mutated D2 dopamine receptors.
    Wilcox RE; Huang WH; Brusniak MY; Wilcox DM; Pearlman RS; Teeter MM; DuRand CJ; Wiens BL; Neve KA
    J Med Chem; 2000 Aug; 43(16):3005-19. PubMed ID: 10956209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
    Wilcox RE; Tseng T; Brusniak MY; Ginsburg B; Pearlman RS; Teeter M; DuRand C; Starr S; Neve KA
    J Med Chem; 1998 Oct; 41(22):4385-99. PubMed ID: 9784114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative molecular field analysis-based prediction of drug affinities at recombinant D1A dopamine receptors.
    Brusniak MY; Pearlman RS; Neve KA; Wilcox RE
    J Med Chem; 1996 Feb; 39(4):850-9. PubMed ID: 8632409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of serine residues to constitutive and agonist-induced signaling via the D2S dopamine receptor: evidence for multiple, agonist-specific active conformations.
    Wiens BL; Nelson CS; Neve KA
    Mol Pharmacol; 1998 Aug; 54(2):435-44. PubMed ID: 9687586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors.
    Perachon S; Schwartz JC; Sokoloff P
    Eur J Pharmacol; 1999 Feb; 366(2-3):293-300. PubMed ID: 10082211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine receptor affinities in vitro and stereotypic activities in vivo of cabergoline in rats.
    Miyagi M; Itoh F; Taya F; Arai N; Isaji M; Kojima M; Ujiie A
    Biol Pharm Bull; 1996 Sep; 19(9):1210-3. PubMed ID: 8889042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of amino acid determinants of dopamine 2 receptor synthetic agonist function.
    Al-Fulaij MA; Ren Y; Beinborn M; Kopin AS
    J Pharmacol Exp Ther; 2007 Apr; 321(1):298-307. PubMed ID: 17204745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of multiple serine/alanine mutations in the transmembrane spanning region V of the D2 dopamine receptor on ligand binding.
    Coley C; Woodward R; Johansson AM; Strange PG; Naylor LH
    J Neurochem; 2000 Jan; 74(1):358-66. PubMed ID: 10617140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural Investigation of the Dopamine-2 Receptor Agonist Bromocriptine Binding to Dimeric D2
    Salmas RE; Seeman P; Stein M; Durdagi S
    J Chem Inf Model; 2018 Apr; 58(4):826-836. PubMed ID: 29537837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of conserved serine residues in the interaction of agonists with D3 dopamine receptors.
    Sartania N; Strange PG
    J Neurochem; 1999 Jun; 72(6):2621-4. PubMed ID: 10349875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of the role of conserved serine residues in the long form of the rat D2 dopamine receptor using site-directed mutagenesis.
    Woodward R; Coley C; Daniell S; Naylor LH; Strange PG
    J Neurochem; 1996 Jan; 66(1):394-402. PubMed ID: 8522980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical identification of the dopamine D2 receptor domains interacting with the adenosine A2A receptor.
    Torvinen M; Kozell LB; Neve KA; Agnati LF; Fuxe K
    J Mol Neurosci; 2004; 24(2):173-80. PubMed ID: 15456930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Universal 3D QSAR Model for Dopamine D
    Zięba A; Żuk J; Bartuzi D; Matosiuk D; Poso A; Kaczor AA
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agonistic actions of pergolide on firing activity of dopamine neurons in substantia nigra compacta area.
    Zhang XX; Jin GZ; Wei YF
    Zhongguo Yao Li Xue Bao; 1995 Sep; 16(5):423-7. PubMed ID: 8701759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine agonists used in the treatment of Parkinson's disease and their selectivity for the D1, D2, and D3 dopamine receptors in human striatum.
    De Keyser J; De Backer JP; Wilczak N; Herroelen L
    Prog Neuropsychopharmacol Biol Psychiatry; 1995 Nov; 19(7):1147-54. PubMed ID: 8787038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of dopamine agonists bromocriptine, pergolide, cabergoline, and SKF-38393 on GDNF, NGF, and BDNF synthesis in cultured mouse astrocytes.
    Ohta K; Kuno S; Mizuta I; Fujinami A; Matsui H; Ohta M
    Life Sci; 2003 Jun; 73(5):617-26. PubMed ID: 12770616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonlinear analysis of partial dopamine agonist effects on cAMP in C6 glioma cells.
    Avalos M; Mak C; Randall PK; Trzeciakowski JP; Abell C; Kwan SW; Wilcox RE
    J Pharmacol Toxicol Methods; 2001; 45(1):17-37. PubMed ID: 11489662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. D1- versus D2-receptor modulation of visuospatial working memory in humans.
    Müller U; von Cramon DY; Pollmann S
    J Neurosci; 1998 Apr; 18(7):2720-8. PubMed ID: 9502829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pergolide binds tightly to dopamine D2 short receptors and induces receptor sequestration.
    Barbier P; Colelli A; Maggio R; Bravi D; Corsini GU
    J Neural Transm (Vienna); 1997; 104(8-9):867-74. PubMed ID: 9451718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine D
    Ågren R; Stepniewski TM; Zeberg H; Selent J; Sahlholm K
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.